Document:

Exhibit 4.2

 

 

 

 

 

InMed
Pharmaceuticals Inc.

AMENDED 2017 Stock Option Plan

 

 

 

     

     

    

 

Inmed pharmaceuticals
Inc.

 

InMed Pharmaceuticals Inc. 2017 Stock Option Plan

 

		1.	PURPOSE OF THE PLAN

 

 1.1 Purpose of this Plan. The purpose of this Plan is to promote the interests of the Company by:

 

		(a)	furnishing certain directors, officers, employees or consultants of the Company or any Affiliate
or other persons as the Compensation Committee may approve with greater incentive to further develop and promote the business and
financial success of the Company;

 

		(b)	furthering the identity of interests of persons to whom Options may be granted with those of the
shareholders of the Company generally through share ownership in the Company; and

 

		(c)	assisting the Company in attracting, retaining and motivating its directors, officers, employees
and consultants.

 

The Company believes that these purposes
may best be effected by granting of Options to Eligible Participants.

 

		2.	DEFINITIONS

 

 2.1 Definitions. In this Plan, unless there is something in the subject matter or context inconsistent therewith, capitalized words and terms will have the following meanings:

 

		(a)	“Affiliate” means, in relation to the Company, an affiliate company as defined
in the Securities Act;

 

		(b)	“Associate” means an associate as defined in the Securities Act;

 

		(c)	“Blackout Period” means: (i) to the extent that the Company has in place an
insider trading policy or any similar policy, such period of time during which trading in securities of the Company by officers,
directors and employees of the Company is prohibited by such policy; (ii) such period or periods, as may be determined from time
to time by the Board of Directors or chief executive officer of the Company, during which the officers, directors and employees
of the Company are prohibited from trading in securities of the Company due to management or the Board of Directors having knowledge
of material undisclosed information with respect the Company or its operations or assets; (iii) the exercise of the Option is prohibited
by applicable law and (iv) shares may not be purchased or sold by certain employees or directors of the Company due to a ’‘lock-up’’
agreement undertaken in connection with an issuance of securities by the Company;

 

    2

     

    

 

		(d)	“Board of Directors” means the board of directors of the Company as constituted
from time to time;

 

		(e)	“Change in Control” means:

 

		(i)	any merger or consolidation in which voting securities of the Company possessing more than fifty
percent (50%) of the total combined voting power of the Company’s outstanding securities are transferred to a person or persons
different from the persons holding those securities immediately prior to such transaction and the composition of the Board of Directors
following such transaction is such that the directors of the Company prior to the transaction constitute less than fifty percent
(50%) of the Board of Directors membership following the transaction;

 

		(ii)	any acquisition, directly or indirectly, by a person or related group of persons (other than the
Company or a person that directly or indirectly controls, is controlled by, or is under common control with, the Company) of beneficial
ownership of voting securities of the Company possessing more than fifty percent (50%) of the total combined voting power of the
Company’s outstanding securities;

 

		(iii)	any acquisition, directly or indirectly, by a person or related group of persons of the right to
appoint a majority of the directors of the Company or otherwise directly or indirectly control the management, affairs and business
of the Company;

 

		(iv)	any sale, transfer or other disposition of all or substantially all of the assets of the Company
to a non-Affiliate; and

 

		(v)	a complete liquidation or dissolution of the Company;

 

provided however, that a Change
in Control shall not be deemed to have occurred if such Change in Control results solely from the issuance, in connection with
a bona fide financing or series of financings by the Company or any of its Affiliates, of voting securities of the Company
or any of its Affiliates or any rights to acquire voting securities of the Company or any of its Affiliates which are convertible
into voting securities;

 

		(f)	“Common Shares” means the common shares in the capital of the Company as constituted
on the Effective Date, provided that if the rights of any Participant are subsequently adjusted pursuant to Article 16 hereof,
“Common Shares” thereafter means the shares or other securities or property which such Participant is entitled to purchase
after giving effect to such adjustment;

 

    3

     

    

 

		(g)	“Compensation Committee” has the meaning ascribed thereto in Section 5.1 of
this Plan;

 

		(h)	“Company” means InMed Pharmaceuticals Inc.;

 

		(i)	“Consultant” means any individual, corporation or other person engaged, from
time to time, to provide valuable services to the Company or an Affiliate;

 

		(j)	“Director” shall mean a member of the Board of Directors.

 

		(k)	“Effective Date” has the meaning ascribed thereto by Section 3.1 of this Plan;

 

		(l)	“Eligible Person” means a director, officer, employee or Consultant of the Company
or an Affiliate or a person otherwise approved by the Compensation Committee;

 

		(m)	“Exercise Price” means the price per Common Share at which a Participant may
purchase Common Shares pursuant to an Option, provided that if such price is adjusted pursuant to Section 16.1 hereof, “Exercise
Price” thereafter means the price per Common Share at which such Participant may purchase Common Shares pursuant to such
Option after giving effect to such adjustment;

 

		(n)	“Fair Market Value” as it relates to Common Shares means:

 

		(i)	where the Common Shares are listed for trading on a Stock Exchange, the closing price of the Common
Shares on such Stock Exchange as determined by the Compensation Committee, for the Trading Session on the day prior to the relevant
time as it relates to an Option; or

 

		(ii)	where the Common Shares are not publicly traded, the value which is determined by the Compensation
Committee to be the fair value of the Common Shares at the relevant time as it relates to an Option, taking into consideration
all factors that the Compensation Committee deems appropriate, including, without limitation, recent sale and offer prices of the
Common Shares in private transactions negotiated at arm’s length;

 

		(o)	“Insider” means:

 

		(i)	an insider as defined in the Securities Act; and

 

		(ii)	an Associate or Affiliate of any person who is an insider;

 

		(p)	“Legacy Options” has the meaning ascribed thereto by Section 3.2 of this Plan;

 

		(q)	“Legal Representative” has the meaning ascribed thereto by Section 10.1 of this
Plan;

 

    4

     

    

 

		(r)	“Merger and Acquisition Transaction” means:

 

		(i)	any merger;

 

		(ii)	any acquisition;

 

		(iii)	any amalgamation;

 

		(iv)	any offer for shares of the Company which if successful would entitle the offeror to acquire all
of the voting securities of the Company; or

 

		(v)	any arrangement or other scheme of reorganization;

 

that results in a Change
in Control;

 

		(s)	“Non Blackout Trading Day” means a day on which (i) a Trading Session occurs,
and (ii) no Blackout Period is in place;

 

		(t)	“Options” means stock options granted hereunder to purchase Common Shares from
treasury pursuant to the terms and conditions hereof and as evidenced by an Option Agreement and “Option” means any
one of them;

 

		(u)	“Option Agreement” means an agreement evidencing an Option, entered into by
and between the Company and an Eligible Person;

 

		(v)	“Outstanding Common Shares” at the time of any share issuance or grant of Options
means the number of Common Shares that are outstanding immediately prior to the share issuance or grant of Options in question,
on a non-diluted basis, or such other number as may be determined under the applicable rules and regulations of all regulatory
authorities to which the Company is subject, including the Stock Exchange;

 

		(w)	“Participant” means a person to whom an Option has been granted under this Plan;

 

		(x)	“Plan” means this InMed Pharmaceuticals Inc. 2017 Stock Option Plan, as the
same may from time to time be supplemented or amended and in effect;

 

		(y)	“Securities Act” means the Securities Act, R.S.B.C. 1996, c.418, as amended
from time to time;

 

		(z)	“Stock Exchange” means such stock exchange or other organized market on which
the Common Shares are listed or posted for trading;

 

		(aa)	“Trading Session” means a trading session on a day which the applicable Stock
Exchange is open for trading;

 

		3.	EFFECTIVE DATE OF PLAN AND APPLICATION

 

 3.1 Effective Date of this Plan. The effective date (the “Effective Date”) of this Plan is March 24, 2017, the date on which this Plan was adopted by the shareholders of the Company.

 

    5

     

    

 

 3.2 Application of this Plan. This Plan applies to all Options granted under this Plan on or after the Effective Date and all stock options of the Company that are outstanding as of the Effective Date (the “Legacy Options”) notwithstanding that such Options were issued under a predecessor stock option plan of the Company. The term “Option” in this Plan shall be read to include all Legacy Options.

 

		4.	COMMON SHARES SUBJECT TO PLAN

 

4.1 Common
Shares Subject to this Plan. Subject to adjustment as provided in Article 16 and the applicable rules and regulations of all
regulatory authorities to which the Company is subject, including the Stock Exchange, the total number of Common Shares issuable
from treasury by the Company pursuant to the Plan and all other securities-based compensation arrangements of the Company (including,
for greater certainty, any Common Shares issuable upon the exercise of any Legacy Options) shall not exceed 20% of the issued and
Outstanding Common Shares on a rolling basis. The number of Common Shares in respect of which Options may be granted pursuant to
this Plan may be increased, decreased or fixed by the Board of Directors, as permitted under the applicable rules and regulations
of all regulatory authorities to which the Company is subject, including the Stock Exchange.

 

4.2 Computation
of Available Shares. For the purposes of computing the number of Common Shares available for grant under this Plan, Common
Shares subject to any Option (or any portion thereof) that have expired or are forfeited, surrendered, cancelled or otherwise terminated
prior to the issuance or transfer of such Common Shares and Common Shares subject to an Option (or any portion thereof) that is
settled in cash in lieu of settlement in Common Shares shall again be available for grant under this Plan. Notwithstanding the
foregoing, any Common Shares subject to an Option that are withheld or otherwise not issued (upon an exercise of any Option) in
order to satisfy the Participant’s withholding obligations or in payment of any Option Exercise Price shall reduce the number
of Common Shares available for grant under the limitations set forth in this Article 4.

 

4.3 Reservation
of Shares. The Board of Directors will reserve for allotment from time to time out of the authorized but unissued Common Shares
sufficient Common Shares to provide for issuance of all Common Shares which are issuable under all outstanding Options.

 

4.4 No
Fractional Shares. No fractional Common Shares may be purchased or issued under this Plan.

 

		5.	ADMINISTRATION OF PLAN

 

5.1 Administration
of Plan. The Board of Directors may at any time appoint a committee (the “Compensation Committee”) to, among
other things, interpret, administer and implement this Plan on behalf of the Board of Directors in accordance with such terms and
conditions as the Board of Directors may prescribe, consistent with this Plan (provided that if at any such time such a committee
has not been appointed by the Board of Directors or the Board of Directors otherwise determines, this Plan will be administered
by the Board of Directors, and in such event references herein to the Compensation Committee shall be construed to be a reference
to the Board of Directors). The Board of Directors will take such steps which in its opinion are required to ensure that the Compensation
Committee has the necessary authority to fulfil its functions under this Plan.

 

    6

     

    

 

5.2 Option
Agreements. Each Option will be evidenced by an Option Agreement which incorporates such terms and conditions as the Compensation
Committee in its discretion deems appropriate and consistent with the provisions of this Plan (and the execution and delivery by
the Company of an Option Agreement with a Participant shall be conclusive evidence that such Option Agreement incorporates terms
and conditions approved by the Compensation Committee and is consistent with the provisions of this Plan). Each Option Agreement
will be executed by the Participant to whom the Option is granted and on behalf of the Company by any member of the Compensation
Committee or any officer of the Company or such other person as the Compensation Committee may designate for such purpose.

 

5.3 Powers
of Compensation Committee. The Compensation Committee is authorized, subject to the provisions of this Plan, to establish from
time to time such rules and regulations, make such determinations and to take such steps in connection with this Plan as in the
opinion of the Compensation Committee are necessary or desirable for the proper administration of this Plan. For greater certainty,
without limiting the generality of the foregoing, the Compensation Committee will have the power, where consistent with the general
purpose and intent of this Plan and subject to the specific provisions of this Plan and any approval of the Stock Exchange, if
applicable:

 

		(a)	to interpret and construe this Plan and any Option Agreement and to determine all questions arising
out of this Plan and any Option Agreement, and any such interpretation, construction or determination made by the Compensation
Committee will be final, binding and conclusive for all purposes;

 

		(b)	to determine to which Eligible Persons Options are granted, and to grant Options;

 

		(c)	to determine the number of Common Shares issuable pursuant to each Option;

 

		(d)	to determine the Exercise Price for each Option;

 

		(e)	to determine the time or times when Options will be granted, vest and be exerciseable, as applicable;

 

		(f)	to determine the vesting terms of Options, which may be based upon the passage of time, continued
employment or service, on the basis of corporate or personal performance objectives, or any combination of the foregoing as determined
by the Compensation Committee;

 

		(g)	to determine any acceleration of vesting;

 

		(h)	to determine if the Common Shares that are subject to an Option will be subject to any restrictions
or repurchase rights upon the exercise or settlement of such Option including, where applicable, the endorsement of a legend on
any certificate representing Common Shares acquired on the exercise or settlement of any Option to the effect that such Common
Shares may not be offered, sold or delivered except in compliance with the applicable securities laws and regulations of Canada,
the United States or any other country and if any rights or restrictions exist they will be described in the applicable Option
Agreement;

 

    7

     

    

 

		(i)	to determine the expiration date for each Option and to extend the period of time for which any
Option is to remain exercisable or may be settled in appropriate circumstances, including, without limitation, in the event of
the Participant’s cessation of employment or service, subject to compliance with Section 8.1(a) and Article 14 of this Plan;

 

		(j)	to prescribe the form of the instruments relating to the grant, exercise, or settlement, as applicable,
and other terms of Options;

 

		(k)	to enter into an Option Agreement evidencing each Option which will incorporate such terms as the
Compensation Committee in its discretion deems consistent with this Plan;

 

		(l)	to take such steps and require such documentation from Eligible Persons which in its opinion are
necessary or desirable to ensure compliance with the rules and regulations of the Stock Exchange and all applicable laws;

 

		(m)	to adopt such modifications, procedures and subplans as may be necessary or desirable to comply
with the provisions of the laws of Canada, the United States and other countries in which the Company or its Affiliates may operate
to ensure the viability and maximization of the benefits from the Options granted to Participants residing in such countries and
to meet the objectives of this Plan; and

 

		(n)	to determine such other matters as provided for herein.

 

		6.	GRANT OF OPTIONS

 

Subject to the rules
set out below, the Compensation Committee or the Board of Directors (or in the case of any proposed Participant who is a member
of the Compensation Committee, the Board of Directors) may from time to time grant to any Eligible Person one or more Options as
the Compensation Committee or the Board of Directors deems appropriate.

 

6.1 Date
Option Granted.  The date on which an Option will be deemed to have been granted under this Plan will be the date on which
the Compensation Committee or the Board of Directors, as applicable, authorizes the grant of such Option or such other date as
may be specified by the Compensation Committee or the Board of Directors, as applicable, at the time of such authorization.

 

6.2 Number
of Common Shares/Maximum Grant. Subject to the applicable rules and regulations of all regulatory authorities to which the
Company is subject, including the Stock Exchange, and Article 4 of this Plan, the number of Common Shares that may be purchased
under any Option will be determined by the Compensation Committee.

 

    8

     

    

 

6.3 Exercise
Price.  The Exercise Price per Common Share under each Option will be determined by the Compensation Committee, in its sole
discretion, but will in no event be less than the Fair Market Value of the date of the grant.

 

6.4 Vesting
Terms. Subject to Sections 8.3 and 16.3 of this Plan, Options shall become vested at such times, in such instalments, and subject
to such terms and conditions as may be determined by the Compensation Committee and set forth in
the applicable Option Agreement.

 

		7.	exercise of options

 

7.1 Exercise
of Options.  Subject to the terms and conditions of this Plan, the Compensation Committee may impose such limitations or conditions
on the exercise or vesting of any Option as the Compensation Committee in its discretion deems appropriate, including limiting
the number of Common Shares for which any Option may be exercised during any period as may be specified by the Compensation Committee
and which number of Common Shares for which such Option may be exercised in any period will be specified in the Option Agreement
with respect to such Option. Each Option Agreement will provide that the Option granted thereunder may be exercised only by notice
signed by the Participant or the Legal Representative of the Participant and accompanied by full payment for the Common Shares
being purchased. Such consideration may be paid in any combination of the following:

 

		(a)	cash, bank draft or certified cheque; or

 

		(b)	such other consideration as the Compensation Committee may permit consistent with applicable laws.

 

As soon as practicable after any exercise
of an Option, a certificate or certificates representing the Common Shares in respect of which such Option is exercised will be
delivered by the Company to the Participant.

 

7.2 Net
Exercises. Notwithstanding Section 7.1, the Compensation Committee may, in its discretion, permit an Option to be exercised
by delivering to the Participant a number Common Shares having an aggregate Fair Market Value (determined as of the date of exercise)
equal to the excess, if positive, of the Fair Market Value of the Common Shares underlying the Options being exercised on the date
of exercise, over the exercise price of the Option for such Common Shares.

 

7.3Conditions.
Notwithstanding any of the provisions contained in this Plan or in any Option Agreement, the Company’s obligation to
issue Common Shares to a Participant pursuant to the exercise of an Option will be subject to, if applicable:

 

		(a)	completion of such registration or other qualification of such Common Shares or obtaining approval
of such governmental authority as the Company will determine to be necessary or advisable in connection with the authorization,
issuance or sale thereof;

 

		(b)	the admission of such Common Shares to listing or quotation on the Stock Exchange; and

 

    9

     

    

 

		(c)	the receipt from the Participant of such representations, agreements and undertakings, including
as to future dealings in such Common Shares, as the Company or its counsel determines to be necessary or advisable in order to
safeguard against the violation of the securities laws of any jurisdiction.

 

		8.	Term of Options

 

8.1 Term
of Options. Unless otherwise determined by the Compensation Committee, each Option granted pursuant to this Plan will, subject
to the provisions of this Plan, expire automatically on the earlier of:

 

		(a)	the date determined by the Compensation Committee and specified in the Option Agreement pursuant
to which such Option is granted, provided that such date may not be, subject to Article 14 later than the earlier of (A) the date
which is the tenth anniversary of the date on which such Option is granted, and (B) the latest date permitted under the applicable
rules and regulations of all regulatory authorities to which the Company is subject, including the Stock Exchange;

 

		(b)	in the event the Participant ceases to be an Eligible Person for any reason, other than the death
of the Participant or the termination of the Participant for cause, such period of time after the date on which the Participant
ceases to be an Eligible Person as may be specified by the Compensation Committee or as specified in an agreement among the Participant
and the Company, and in the absence of such specification or agreement, will be deemed to be the date that is three months following
the date on which the Company provides notice in writing to the Participant that the Participant has ceased to be an Eligible Person;

 

		(c)	in the event of the termination of the Participant as a director, officer, employee or Consultant
of the Company or an Affiliate for cause, the date of such termination;

 

		(d)	in the event of the death of a Participant prior to: (A) the Participant ceasing to be an
Eligible Person; or (B) the date which is the number of days specified by the Compensation Committee pursuant to subparagraph
(b) above from the date on which the Participant ceased to be an Eligible Person; the date which is one year after the date of
death of such Participant or such other date as may be specified by the Compensation Committee and which period will be specified
in the Option Agreement with the Participant with respect to such Option; and

 

		(e)	notwithstanding the foregoing provisions of subparagraphs (b), (c) and (d) of this Section
8.1, the Compensation Committee may, subject Article 15 and to regulatory approval, at any time prior to expiry of an Option extend
the period of time within which an Option may be exercised by a Participant who has ceased to be an Eligible Person, but such an
extension shall not be granted beyond the original expiry date of the Option as provided for in subparagraph (a) above.

 

    10

     

    

 

8.2 Options
Cease to Vest. Notwithstanding the foregoing, except as expressly permitted by the Compensation Committee, all Options will
cease to vest as at the date upon which the Participant ceases to be an Eligible Person.

 

8.3 Accelerated
Vesting of Options on Death. In the event of the death of the Participant prior to the Participant ceasing to be an Eligible
Person, the Compensation Committee may exercise its discretion to provide for the immediate vesting of all, or a portion of, the
then unvested Options of such Participant.

 

8.4 Termination
of a Participant for Cause. Notwithstanding any other provision hereof or in any Option Agreement, in the case of a Participant’s
termination for cause, any and all then outstanding Options granted to the Participant, whether or not vested, shall be immediately
forfeited and cancelled, without any consideration therefore, and any and all rights of such Participant with respect to and arising
from this Plan or any Option Agreement shall terminate, as of the commencement of the date that notice of such termination is given,
without regard to any period of reasonable notice or any salary continuance, unless otherwise determined by the Compensation Committee.

 

		9.	change in status

 

9.1 A
change in the status, office, position or duties of a Participant from the status, office, position or duties held by such Participant
on the date on which the Option was granted to such Participant will not result in the termination of the Option granted to such
Participant provided that such Participant remains a director, officer, employee or Consultant of the Company or an Affiliate.

 

		10.	non-transferability of Options

 

10.1 Each
Option Agreement will provide that the Options granted thereunder are not transferable or assignable and may be exercised or settled,
as the case may be, only by the Participant or, in the event of the death of the Participant or the appointment of a committee
or duly appointed attorney of the Participant or of the estate of the Participant on the grounds that the Participant is incapable,
by reason of physical or mental infirmity, of managing their affairs, the Participant’s legal representative or such committee
or attorney, as the case may be (the “Legal Representative”).

 

		11.	representations and covenants of participants

 

11.1 Each
Option Agreement will contain representations and covenants of the Participant that:

 

		(a)	the Participant is a director, officer, employee, or Consultant of the Company or an Affiliate
or a person otherwise approved as an “Eligible Person” under this Plan by the Compensation Committee;

 

		(b)	the Participant has not been induced to enter into such Option Agreement by the expectation of
employment or continued employment with the Company or an Affiliate;

 

    11

     

    

 

		(c)	the Participant is aware that the grant of the Options and the issuance by the Company of Common
Shares thereunder are exempt from the obligation under applicable securities laws to file a prospectus or other registration document
qualifying the distribution of the Options or the Common Shares to be distributed thereunder under any applicable securities laws;

 

		(d)	upon each exercise or settlement of an Option, the Participant, or the Legal Representative of
the Participant, as the case may be, will, if requested by the Company, represent and agree in writing that the person is, or the
Participant was, a director, officer, employee or Consultant of the Company or an Affiliate or a person otherwise approved as an
“Eligible Person” under this Plan by the Compensation Committee and has not been induced to purchase the Common Shares
by expectation of employment or continued employment with the Company or an Affiliate, and that such person is not aware of any
commission or other remuneration having been paid or given to others in respect of the trade in the Common Shares; and

 

		(e)	if the Participant or the Legal Representative of the Participant exercises or settles the Option,
the Participant or the Legal Representative, as the case may be, will prior to and upon any sale or disposition of any Common Shares
received pursuant to the exercise or settlement of the Option, comply with all applicable securities laws and all applicable rules
and regulations of all regulatory authorities to which the Company is subject, including the Stock Exchange, and will not offer,
sell or deliver any of such Common Shares, directly or indirectly, in the United States or to any citizen or resident of, or any
corporation, partnership or other entity created or organized in or under the laws of, the United States, or any estate or trust
the income of which is subject to United States federal income taxation regardless of its source, except in compliance with the
securities laws of the United States.

 

		12.	provisions related to share issuances

 

12.1 Each
Option Agreement will contain such provisions as in the opinion of the Compensation Committee are required to ensure that no Common
Shares are issued on the exercise or settlement of an Option unless the Compensation Committee is satisfied that the issuance of
such Common Shares will be exempt from all registration or qualification requirements of applicable securities laws and will be
permitted under the applicable rules and regulations of all regulatory authorities to which the Company is subject, including the
Stock Exchange. In particular, if required by any regulatory authority to which the Company is subject, including the Stock Exchange,
an Option Agreement may provide that shareholder approval to the grant of an Option must be obtained prior to the exercise or settlement
of the Option or to the amendment of the Option Agreement.

 

		13.	withholding tax

 

13.1 The
Participant will be solely responsible for paying any applicable withholding taxes arising from the grant, vesting, exercise or
settlement of any Option and payment is to be made in a manner satisfactory to the Company. Notwithstanding the foregoing, the
Company will have the right to withhold from any Option or any Common Shares issuable pursuant to an Option or from any cash amounts
otherwise due or to become due from the Company to the Participant, an amount equal to any such taxes.

 

		14.	exercise and settlement of Options during blackout periods

 

14.1 Adjustment
for Exercise of Options during Blackout Periods. Where the expiry date of an Option occurs during a Blackout Period or within
twenty Non-Blackout Trading Days following the end of a Blackout Period, the expiry date for such Option shall be the date which
is twenty Non-Blackout Trading Days following the end of such Blackout Period.

 

    12

     

    

 

		15.	SUSPENSION, AMENDMENT OR TERMINATION OF PLAN

 

15.1 Suspension,
Amendment or Termination of Plan. The Compensation Committee will have the right at any time to suspend, amend or terminate
this Plan and, subject to Section 15.2, may:

 

		(a)	with approval of shareholders of the Company by ordinary resolution make any amendment to any Option
Agreement or the Plan; and

 

		(b)	without approval of shareholders of the Company make the following amendments to any Option Agreement
or the Plan:

 

		(i)	amendments of a clerical nature, including but not limited to the correction of grammatical or
typographical errors or clarification of terms;

 

		(ii)	amendments to reflect any requirements of any regulatory authorities to which the Company is subject,
including the Stock Exchange;

 

		(iii)	subject to the terms and conditions of the Plan, amendments to vesting provisions of Option Agreements;

 

		(iv)	extend the term of Options held by non-Insiders of the Company;

 

		(v)	reduce the Exercise Price per Common Share under any Option held by non-Insiders of the Company
or replace such Option with a lower Exercise Price per Common Share under such replacement Option; and

 

		(vi)	amendments which provide cashless exercise features to an Option that require the full deduction
of the number of underlying Common Shares from the total number of Common Shares subject to the Plan.

 

Notwithstanding the foregoing, all procedures
and necessary approvals required under the applicable rules and regulations of all regulatory authorities to which the Company
is subject shall be complied with and obtained in connection with any such suspension, termination or amendment to the Plan or
amendments to any Option Agreement.

 

    13

     

    

 

15.2 Limitations.
In exercising its rights pursuant to Section 15.1, the Compensation Committee will not have the right to:

 

		(a)	make any amendment to any Option Agreement or the Plan which requires the approval of the shareholders
of the Company under the applicable rules and regulations of the regulatory authorities to which the Company is subject, including
the Stock Exchange, without first obtaining such required shareholder approval except as permitted pursuant to Article 16;

 

		(b)	affect in a manner that is adverse or prejudicial to, or that impairs, the benefits and rights
of any Participant under any Option previously granted under this Plan (except as permitted pursuant to Article 16 and except for
the purpose of complying with applicable securities laws or the bylaws, rules and regulations of any regulatory authority to which
the Company is subject, including the Stock Exchange);

 

		(c)	decrease the number of Common Shares which may be purchased pursuant to any Option (except as permitted
pursuant to Article 16) without the consent of such Participant;

 

		(d)	set the Exercise Price of any Option below the Fair Market Value of such Option on the date of
grant;

 

		(e)	increase the Exercise Price at which Common Shares may be purchased pursuant to any Option (except
as permitted pursuant to Article 16) without the consent of such Participant;

 

		(f)	extend the term of any Option beyond a period of ten years or the latest date permitted under the
applicable rules and regulations of all regulatory authorities to which the Company is subject, including the Stock Exchange; or

 

		(g)	grant any Option if this Plan is suspended or has been terminated.

 

15.3 Powers
of Compensation Committee Survive Termination. The full powers of the Compensation Committee as provided for in this Plan will
survive the termination of this Plan until all Options have been exercised or settled in full or have otherwise expired.

 

		16.	ADJUSTMENTS

 

16.1 Adjustments.
Appropriate adjustments in the number of Common Shares subject to this Plan, as regards Options granted or to be granted, in
the Option Exercise Price of an Option, in the number of Common Shares to be issued or cash payments to be made in respect of the
settlement of any Option, or any other matter will be conclusively determined by the Compensation Committee to give effect to adjustments
in the number of Common Shares resulting from subdivisions, consolidations, substitutions, or reclassifications of the Common Shares,
the payment of stock dividends by the Company (other than dividends in the ordinary course) or other relevant changes in the capital
of the Company or from a proposed merger, amalgamation or other corporate arrangement or reorganization involving the exchange
or replacement of Common Shares of the Company for those in another corporation. Any dispute that arises at any time with respect
to any such adjustment will be conclusively determined by the Compensation Committee, and any such determination will be binding
on the Company, the Participant and all other affected parties.

 

    14

     

    

 

16.2 Merger
and Acquisition Transaction. In the event of a Merger and Acquisition Transaction or proposed Merger and Acquisition Transaction,
the Compensation Committee, at its option, may do any of the following:

 

		(a)	the Compensation Committee may, in a fair and equitable manner, determine the manner in which all
unexercised Options or unsettled Options granted under this Plan will be treated including, without limitation, requiring the acceleration
of the time for the exercise or settlement of Options by the Participants, the time for the fulfilment of any conditions or restrictions
on such exercise or settlement, and the time for the expiry of such rights; or

 

		(b)	the Compensation Committee or any corporation which is or would be the successor to the Company
or which may issue securities in exchange for Common Shares upon the Merger and Acquisition Transaction becoming effective may
offer any Participant the opportunity to obtain a new or replacement awards over any securities into which the Common Shares are
changed or are convertible or exchangeable, on a basis proportionate to the number of Common Shares under Option, including Exercise
Price, as applicable (and otherwise substantially upon the terms of the Option being replaced, or upon terms no less favourable
to the Participant) including, without limitation, the periods during which the Option may be exercised or settled and expiry dates
of such Options; and in such event, the Participant shall, if he accepts such offer, be deemed to have released his Option over
the Common Shares and such Option shall be deemed to have lapsed and be cancelled; or

 

		(c)	the Compensation Committee may commute for or into any other security or any other property or
cash, any Option that is still capable of being exercised or settled, upon giving to the Participant to whom such Option has been
granted at least 30 days written notice of its intention to commute such Option, and during such period of notice, the Option,
to the extent it has not been exercised or settled, may be exercised or settled by the Participant without regard to any vesting
conditions attached thereto; and on the expiry of such period of notice, the unexercised or unsettled portion of the Option shall
lapse and be cancelled.

 

Section 16.1 and subsections (a), (b) and
(c) of this Section 16.2 are intended to be permissive and may be utilized independently or successively in combination or otherwise,
and nothing therein contained shall be construed as limiting or affecting the ability of the Compensation Committee to deal with
Options in any other manner. All determinations by the Compensation Committee under this Section will be final, binding and conclusive
for all purposes.

 

    15

     

    

 

16.3 Accelerated
Vesting on Change in Control. Notwithstanding any other provision hereof, all outstanding Options (including, for greater certainty,
any outstanding Legacy Options) shall become immediately vested and exercisable upon: (i) the Company entering into a definitive
agreement with respect to a Merger and Acquisition Transaction; or (ii) a Change in Control of the Company. For greater clarity,
any Options that become vested in the circumstances contemplated by this Section 16.3 may only be exercised on a Non Blackout Trading
Day.

 

16.4 Limitations.
The grant of Options under this Plan will in no way affect the Company’s right to adjust, reclassify, reorganize or otherwise
change its capital or business structure or to merge, amalgamate, reorganize, consolidate, dissolve, liquidate or sell or transfer
all or any part of its business or assets or engage in any like transaction.

 

16.5 No
Fractional Shares. No adjustment or substitution provided for in this Article 16 will require the Company to issue a fractional
share in respect of any Option and the total substitution or adjustment with respect to each Option will be limited accordingly.

 

		17.	GENERAL

 

17.1 No
Rights as Shareholder. Nothing herein or otherwise shall be construed so as to confer on any Participant any rights as a shareholder
of the Company with respect to any Common Shares reserved for the purpose of any Option.

 

17.2 No
Effect on Employment. Nothing in this Plan or any Option Agreement will confer upon any Participant any right to continue in
the employ of or under contract with the Company or an Affiliate or affect in any way the right of the Company or any such Affiliate
to terminate his or her employment at any time or terminate his or her consulting contract; nor will anything in this Plan or any
Option Agreement be deemed or construed to constitute an agreement, or an expression of intent, on the part of the Company or any
such Affiliate to extend the employment of any Participant beyond the time that he or she would normally be retired pursuant to
the provisions of any present or future retirement plan of the Company or an Affiliate or any present or future retirement policy
of the Company or an Affiliate, or beyond the time at which he or she would otherwise be retired pursuant to the provisions of
any contract of employment with the Company or an Affiliate. Neither any period of notice nor any payment in lieu thereof upon
termination of employment shall be considered as extending the period of employment for the purposes of the Plan.

 

17.3 No
Fettering of Directors’ Discretion. Nothing contained in this Plan will restrict or limit or be deemed to restrict or
limit the right or power of the Board of Directors in connection with any allotment and issuance of Common Shares which are not
allotted and issued under this Plan including, without limitation, with respect to other compensation arrangements.

 

17.4 Applicable
Law. The Plan and any Option Agreement granted hereunder will be governed, construed and administered in accordance with the
laws of the Province of British Columbia and the laws of Canada applicable therein.

 

17.5 Interpretation.
References herein to any gender include all genders and to the plural includes the singular and vice versa. The insertion of
headings are for convenience of reference only and will not affect the construction or interpretation of this Plan.

 

17.6 Reference.
This Plan may be referred to as the “InMed Pharmaceuticals Inc. 2017 Stock Option Plan”.

 

 

16Exhibit 4.3 

 

 

 

STOCK OPTION PLAN - OPTION AGREEMENT

 

This Option Agreement is entered into between
INMED PHARMACEUTICALS INC. (the “Company”) and the Optionee named below pursuant to the Company Stock Option Plan (the
“Plan”), a copy of which is attached hereto, and confirms that:

 

	1.	on _____________ (the “Grant Date”);

 

	2.	_______________ (the “Optionee”);

 

	3.	was granted the option (the “Option”) to purchase ________ Common Shares (the “Option
Shares”) of the Company;

 

	4.	for the price (the “Option Price”) of ______ per share;

 

	5.	The following vesting provisions:

 

	6.	this Option terminates on _________ (the “Expiry Date”);

 

all on the terms and subject to the conditions
set out in the Plan. The Option Shares shall continue to be exercisable until the termination or cancellation thereof as provided
in this Option Agreement and the Plan. However, should the Optionee cease to be an officer, director, employee or consultant (“Eligible
Person”) due to his or her termination by the Company other than for cause, or due to his or her voluntary resignation, the
Option then held by the Optionee shall be exercisable to acquire vested unissued Option Shares at any time up to but not after
the earlier of the Expiry Date and the date which is ninety (90) days after the Optionee ceases to be an Eligible Person.

 

To exercise your Option, deliver a written
notice specifying the number of Optioned Shares you wish to acquire, together with cash or a certified cheque payable to the Company
for the aggregate Option Price, to the Company. A certificate for the Optioned Shares so acquired will be issued by the transfer
agent as soon as practicable thereafter.

 

By signing this Option Agreement, the Optionee
acknowledges that the Optionee has read and understands the Plan and agrees to the terms and conditions of the Plan and this Option
Agreement.

 

Acknowledgement – Personal Information

 

The undersigned hereby acknowledges and
consents to:

 

	(a)	the disclosure to the Toronto Stock Exchange and all other regulatory authorities of all personal
information of the undersigned obtained by the Company; and

 

	(b)	the collection, use and disclosure of such personal information by the Toronto Stock Exchange and
all other regulatory authorities in accordance with their requirements, including the provision to third party service providers,
from time to time.

 

Suite 310 – 815 West Hastings St.,
Vancouver, BC V6C 1B4 | T: 604.669.7207 | F: 778.945.6800 | www.inmedpharma.com

 

     

     

    

 

IN WITNESS WHEREOF the parties hereto have
executed this Option Agreement with an effective date of the _____ day of ___________, 20__.

 

	 	 	INMED PHARMACEUTICALS INC.
	 	 	 
	 	 	 
	Signature	 	Per:	 
	 	 	 	Authorized Signatory
	 	 	 
	Print Name	 	 
	 	 	 
	 	 	 
	Address	 	 

 

     

     

    

 

 

 

 

STOCK OPTION PLAN – EXERCISE NOTICE

  

		To:	INMED PHARMACEUTICALS INC. (the “Company”)

 

The undersigned hereby irrevocably gives
notice, pursuant to the Company’s stock option plan (the “Plan”), of the exercise of the option to acquire and
hereby subscribes for:

 

		(a)	all of the shares; or

 

		(b)	________________ of the shares, which are the subject of the option certificate attached
hereto.

 

Calculation of the total exercise price:

 

	(i)	number of shares to be acquired on exercise:	 	 	 shares
	 	 	 	 
	(ii)	multiplied by the exercise price per share:	$	 	 
	 	 	 	 
	(iii)   	withholding taxes calculated 	$	 	 
	 	 	 	 
	 	TOTAL EXERCISE PRICE, enclosed herewith:    	$	 	 

 

The undersigned tenders herewith a certified
cheque, bank draft or wire transfer in an amount equal to the total exercise price of the aforesaid shares, as calculated above,
and directs the Company to issue the share certificate evidencing said shares in the name of the undersigned to be mailed to the
undersigned at the following address:

 

____________________________________________

 

____________________________________________

 

____________________________________________

 

DATED the __________ day of ____________, 20__________.

 

	 	 
	 	Signature of Option Holder
	 	 
	 	 
	 	Name of Option Holder (please print)

 

 

Suite 310 – 815 West Hastings St.,
Vancouver, BC V6C 1B4 | T: 604.669.7207 | F: 778.945.6800 | www.inmedpharma.com

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}]]